prostaglandin i2 receptor

MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).

AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.

Prostaglandin I2 is an unstable prostaglandin compound that inhibits platelet aggregation and induces vasodilation in the pulmonary vasculature via the "I prostanoid" (IP) receptor. AFP 07, a 7,7-difluoroprostacyclin derivative, serves as a selective and potent agonist for the IP receptor (Ki=0.561 nM). It exhibits weaker affinity for EP receptors, with a Ki value of > 100 nM for EP1-3 and > 10 nM for EP4. The compound 16(R)-AFP 07 free acid is an enantiomer of AFP 07. Its biological properties, particularly those involving IP and EP receptors, are yet to be fully assessed.

ONO 1301 is a prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase, and it suppresses pancreatic fibrosis in the DBTC-induced chronic pancreatitis model by inhibiting monocyte activity through both direct effects of ONO 1301 and induction of hepatocyte growth factor. ONO 1301 also promoting HGF synthesis and elevating intracellular cyclic AMP levels via IP-receptor signaling, highlighting its therapeutic relevance in fibrotic disease and inflammation research.

Clinprost is a Vasodilator (peripheral), Platelet aggregation inhibitor, and Prostaglandin I2 receptor agonist